Cancer therapy using CLDN6 target-directed antibodies in vivo

US9718886B2 · kind B2 · utility

Assignees

• Ganymed Pharmaceuticals GmbH · DE
• Johannes Gutenberg-Universität Mainz · DE

Inventors

• Ugur Sahin · Mainz, DE
• Ozlem Tureci · Homburg, DE
• Michael Koslowski · Mainz, DE
• Korden Walter · Mainz, DE
• Maria Kreuzberg · Mainz, DE
• Sylvia Luxen · Mannheim, DE

Key dates

• Filing date: Jul 4, 2011
• Grant date: Aug 1, 2017
• Expiry date: Aug 11, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to the treatment and/or prevention of tumor diseases associated with cells expressing CLDN6, in particular cancer and cancer metastasis using antibodies which bind to CLDN6. The present application demonstrates that the binding of antibodies to CLDN6 on the surface of tumor cells is sufficient to inhibit growth of the tumor and to prolong survival and extend the lifespan of tumor patients. Furthermore, binding of antibodies to CLDN6 is efficient in inhibiting growth of CLDN6 positive germ cell tumors such as teratocarcinomas or embryonal carcinomas, in particular germ cell tumors of the testis.